Shanghai Key Laboratory of Vascular Biology, State Key Laboratory of Medical Genomics, Shanghai, China.
Department of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
J Hum Hypertens. 2018 Sep;32(8-9):564-571. doi: 10.1038/s41371-018-0077-7. Epub 2018 Jun 5.
Recent research suggested that certain small leucine-rich repeat proteoglycans (SLRPs) were involved in the development of atherosclerosis. The present study investigated the relationship between carotid atherosclerosis plaque and the circulating levels of some SLRPs, including decorin, lumican, and osteoglycin, in essential hypertension. In total, 176 essential hypertensive patients were recruited (mean age 62.1 ± 9.4, male 56.8%) in this study and were classified into two groups: patients with carotid artery plaque (n = 105, 60%) and patients without carotid artery plaque (n = 71, 40%). Patients with carotid artery plaque had higher serum concentration of lumican than patients without carotid plaque (58.0 ± 1.6 vs. 52.3 ± 2.1 ng/ml, p = 0.04) after adjusting for conventional cardiovascular risk factors. There were no differences in decorin and osteoglycin between the two groups. Multivariable logistic regression analysis revealed that lumican levels (Odds ratio (OR) per standard deviation increase, 1.598; 95% confidence interval (CI), 1.012 ~ 2.523; p = 0.04), 24-h mean systolic blood pressure (OR, 1.045; 95% CI, 1.012 ~ 1.079; p = 0.006) and the use of angiotensin receptor blocker (OR, 2.813; 95% CI, 1.023 ~ 7.734; p = 0.045) were independently associated with carotid artery plaque. Besides carotid artery plaque, lumican was related to impaired glucose tolerance (r = 0.162, p = 0.046) and adversely related to osteoglycin (r = - 0.273, p < 0.001), whereas unrelated to age, sex, BMI, diabetes, blood pressure, serum lipids, high-sensitivity C-reactive protein, or carotid intima-media thickness in univariate correlation analyses. Circulating lumican was independently associated with carotid atherosclerosis plaque in essential hypertensive patients, indicating that SLRPs might be used as a promising molecular marker for atherosclerosis.
最近的研究表明，某些小富含亮氨酸的重复蛋白聚糖 (SLRPs) 参与了动脉粥样硬化的发展。本研究调查了原发性高血压患者颈动脉粥样硬化斑块与某些 SLRPs（包括核心蛋白聚糖、赖氨聚糖和骨桥蛋白）循环水平之间的关系。
在这项研究中，共招募了 176 名原发性高血压患者（平均年龄 62.1±9.4 岁，男性 56.8%），并将他们分为两组：颈动脉斑块患者（n=105，60%）和无颈动脉斑块患者（n=71，40%）。
在校正了常规心血管危险因素后，颈动脉斑块患者的血清中赖氨聚糖的浓度高于无颈动脉斑块患者（58.0±1.6 与 52.3±2.1ng/ml，p=0.04）。
两组之间核心蛋白聚糖和骨桥蛋白没有差异。
多变量逻辑回归分析显示，赖氨聚糖水平（每标准差增加的优势比，1.598；95%置信区间，1.0122.523；p=0.04）、24 小时平均收缩压（OR，1.045；95%CI，1.0121.079；p=0.006）和血管紧张素受体阻滞剂的使用（OR，2.813；95%CI，1.023~7.734；p=0.045）与颈动脉斑块独立相关。
除了颈动脉斑块，赖氨聚糖与葡萄糖耐量受损相关（r=0.162，p=0.046），与骨桥蛋白呈负相关（r=-0.273，p<0.001），而在单变量相关分析中与年龄、性别、BMI、糖尿病、血压、血脂、高敏 C 反应蛋白或颈动脉内膜中层厚度无关。
循环赖氨聚糖与原发性高血压患者颈动脉粥样硬化斑块独立相关，表明 SLRPs 可能可作为动脉粥样硬化的有前途的分子标志物。
